@article{5e0f75393f2a49c3851bad17d9478359,
title = "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen",
abstract = "Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.",
author = "Ma, {Xiao Jun} and Zuncai Wang and Ryan, {Paula D.} and Isakoff, {Steven J.} and Anne Barmettler and Andrew Fuller and Beth Muir and Gayatry Mohapatra and Ranelle Salunga and Tuggle, {J. Todd} and Yen Tran and Diem Tran and Ana Tassin and Paul Amon and Wilson Wang and Wei Wang and Edward Enright and Kimberly Stecker and Eden Estepa-Sabal and Barbara Smith and Jerry Younger and Ulysses Balis and James Michaelson and Atul Bhan and Karleen Habin and Baer, {Thomas M.} and Joan Brugge and Haber, {Daniel A.} and Erlander, {Mark G.} and Sgroi, {Dennis C.}",
note = "Funding Information: We thank Leif Ellisen, Emmett Schmidt, and Michael Overholtzer for helpful discussions, and Philip McQuary, Anitha Male, Sonika Dahiya, Teresa Alvarez, Leah Gaumont, Katrina Mesina, Marc Laughlin, and Brian M. Zhang for technical assistance. This work is supported in part by grants from the Avon Foundation, the Department of Defense Grants DAMD17-03-1-0428 (to D.C.S.) and the National Cancer Institute-Specialized Programs of Research Excellence (NCI SPORE) in Breast Cancer at Massachusetts General Hospital. X.-J.M., R.S., J.T.T., Y.T., D.T., A.T., P.A., Wilson Wang, Wei Wang, E.E., K.S., E.E.-S., T.M.B., and M.G.E. are employees of Arcturus Bioscience Inc. X.-J.M., M.G.E., and D.C.S. are named inventors on a patent to use the HoxB13:IL17BR expression ratio to ascertain breast cancer prognosis. ",
year = "2004",
month = jun,
doi = "10.1016/j.ccr.2004.05.015",
language = "English (US)",
volume = "5",
pages = "607--616",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",
}